An enlarged thyroid gland is termed as goiter. The thyroid usually grows anteriorly and/or laterally. The thyroid gland is covered by thin muscles, subcutaneous fat tissue, and skin and does not meet any resistance while growing. When enlarged, it is typically visible to plain eyes and easily palpable. If the thyroid gland grows inferiorly and passes through the thoracic inlet into the thoracic cavity, it is termed as "substernal goiter." An alternative term is "retrosternal goiter". Substernal goiter may involve one or both the lobes of the thyroid gland and may cause deviation and/or compression of the trachea, and less commonly esophagus or venous structures. Tracheal compression has been reported in 35% to 73% of substernal goiters. Up to 10% of substernal goiters are located in the posterior mediastinum, and 90% of that 10% posterior mediastinal goiters are right-sided, as left-sided subclavian arteries and the aortic arch do not allow for left-sided expansion. Some studies define substernal goiter, if any portion of the thyroid gland goes down through thoracic inlet, whereas others define if 50% or more of the thyroid is below the thoracic inlet. The difference in the definition explains, in part, the variability of results among studies. If the lower tip of the thyroid goes back above the thoracic inlet when the patient extends his/her neck, the abnormality is positional and does not count as substernal goiter.
The etiology of substernal goiter is the same as cervical goiter. Descent of cervical goiter through the thoracic inlet is considered to be the cause, because substernal goiters get their blood supply from the neck, mainly from the inferior thyroid artery. Ectopic thyroid tissue in the chest causing de novo substernal goiter is rare, accounting for only 2% of all substernal goiters. Sometimes cervical goiters that descend to the thoracic cavity lose their continuity with thyroid tissue in the neck and seem like isolated occurrences in the chest. A substernal goiter may only be connected to a cervical goiter with only a fascial extension.
The prevalence of substernal goiter in the general population is unknown because of a lack of epidemiological studies. Because of the widespread use of imaging, more cases of substernal goiter are expected to come to clinical attention. Substernal goiter is more commonly diagnosed after age 50 years and is four times more common in females. A recent surgical series reported the rate of substernal goiter as 7% among patients who underwent thyroid surgery.
Patients may not have any symptoms, and a chest X-ray, CT, or MRI may incidentally detect substernal goiter. Symptoms are typically mechanical in nature, and clinical manifestations due to hypo or hyperthyroidism can also be present. The patient may complain of local obstructive or compressive symptoms. The most common obstructive symptom is exertional dyspnea, followed by choking sensation, cough, and stridor. As patients with substernal goiter are usually in their sixth decade or later, the etiology of dyspnea must accurately be determined because other comorbidities common in the elderly, like chronic obstructive pulmonary disease (COPD), asthma, or congestive heart failure can also cause dyspnea. Other symptoms may include difficulty in swallowing due to esophageal compression, hoarseness due to recurrent laryngeal nerve compression, prominent jugular veins, or superior vena cava syndrome due to compression of venous structures. As goiter grows slowly, the condition can be asymptomatic or insidious. Enlargement of thyroid tissue at the thoracic inlet or in the chest cavity is the cause of obstructive symptoms. These anatomical areas have confinements and are unable to accommodate the enlarging goiter.
Hyperthyroidism and hypothyroidism may coexist with substernal goiter and may have their respective signs. Enlarged cervical component of the substernal goiter may be visible or palpable. If there is compression of the trachea, stridor might be audible. Stridor refers to obstruction of the airway outside the chest cavity, producing a high-pitched sound heard more on inspiration. This differs from wheezing, which is an obstruction of the lower respiratory tract that causes a continuous whistling sound heard more during expiration.
Pemberton sign may be sought during physical examination. The patient is asked to raise both arms until medial parts touch to lateral sides of the head for at least a minute. The development of facial congestion, bulging of neck veins, hoarseness or dyspnea indicates a positive Pemberton sign, indicating compression at the thoracic inlet. Arm elevation spirometry with flow volume loops has been suggested to increase the sensitivity to detect upper airway obstruction and also as an objective assessment of Pemberton sign. “Corking” of the thyroid at the thoracic inlet is believed to cause compression of surrounding anatomical structures and positive Pemberton sign. A cork effect is the result of either goiter descending into the thoracic cavity or thoracic inlet elevation towards the neck. Corking may cause symptoms if the patient with substernal goiter flexes or hyperflexes his/her head. MR angiography of a patient with a positive Pemberton sign showed that clavicles moved and compressed external and internal jugular veins at the subclavian vein confluence against the enlarged thyroid rather than a “cork effect” and resembled a nutcracker, the explanation being medial clavicular heads compressing venous structures against enlarged thyroid within the narrowed thoracic inlet.
TSH level needs to be measured. Total or free T4, total or free T3 can be obtained if TSH is abnormal. Alternatively, free T4, free T3, and TSH can be measured at once to assess thyroid hormone status. At the initial evaluation, some healthcare professionals also obtain anti-thyroid peroxidase (anti-TPO) and anti-thyroglobulin antibodies to assess for Hashimoto’s thyroiditis, which may coexist with substernal goiter.
Thyroid ultrasound is recommended to assess the cervical component of the goiter. Thyroid ultrasound cannot assess the extent and characteristics of the intrathoracic portion of the substernal goiter, because ultrasound waves cannot penetrate bone and do not propagate well through the air in the lungs.
Chest X-ray may show an upper mediastinal mass and tracheal deviation and/or compression.
The preferred imaging modality is computed tomography (CT) or magnetic resonance imaging (MRI) of the chest. They accurately assess the size and extent of substernal goiter and its relationship with other anatomic structures. Iodinated contrast use for CT scanning can induce hyperthyroidism and precludes nuclear medicine thyroid scan until iodine load is cleared from the body. Nuclear medicine thyroid (iodine or technetium) scan may show thyroid tissue in the thoracic cavity. The absence of uptake may indicate a cold nodule in the mediastinum and does not rule out substernal goiter.
Barium esophagography or upper endoscopy can be considered if the predominant symptom is dysphagia, but none of them are routine.
The most important and recommended imaging modality is CT of the chest. CT allows for characterization of the thyroid mass, its size, morphology, anatomic relationship with surrounding structures, enables detection of tracheal deviation, and quantification of tracheal compression. If the tracheal dimension is 10 mm or less, surgical intervention is required.
A pulmonary function test with a flow-volume loop study is required. Even if the patient has no symptoms, pulmonary function tests may be abnormal. Substernal goiter may cause a blunted flow-volume loop with an almost equal degree of flow limitation in both inspirium and expirium with flattening of both limbs of the flow-volume loop, indicating a mechanical fixed upper airway obstruction. Pulmonary function tests are helpful to differentiate from other causes of dyspnea, like COPD.
Thyroid cancer has been reported in 0-19% of substernal goiters. A recent guideline on surgical management of adult thyroid disease notes the risk of malignancy in substernal goiter as 9% to 13%. Although thyroid fine-needle aspiration is the gold standard for cervical thyroid nodules, it is not recommended for substernal goiters. One of the side effects of thyroid fine-needle aspiration is hemorrhage. Bleeding inside a substernal goiter or a substernal thyroid nodule may cause sudden enlargement and respiratory compromise. Fine needle insertion into the thoracic cavity has the potential to cause pneumothorax. Fine needle aspiration of a substernal goiter or a nodule within a substernal goiter is not recommended.
If the patient has hypo or hyperthyroidism, they should be addressed. The treatment of symptomatic substernal goiter is surgery. The management of asymptomatic substernal goiter is controversial with no agreed-upon single approach. If the patient is asymptomatic, absence of a fixed upper airway obstruction or significant compression of the trachea, an expectant observation to monitor for symptoms and signs can be considered. A close watch on any change in the size of the goiter, tracheal diameter, and thyroid functions is necessary in such cases. With this approach, the patient should avoid iodine-containing supplements, iodine-containing multivitamins, iodine-containing medications, and iodinated contrast agents to avoid the development of iodine-induced hyperthyroidism. Expectant monitoring involves periodic thyroid function tests, CT of the chest in one year, and if stable less frequently. If no abnormalities on observed parameters develop, periodic monitoring continues. If there is a growth of substernal goiter, evolving compression of trachea manifesting with a decrease in tracheal size, development of thyroid autonomy with hyperthyroidism, then surgery is the next step. If the patient has hyperthyroidism, an antithyroid drug, and a beta-blocker should be given two weeks before surgery, provided that there are no contraindications to beta-blockers. Also, an inorganic iodine solution should be given 7-10 days before surgery to prevent a thyroid storm. If the patient has only subclinical hyperthyroidism, there is no need to prepare the patient for surgery.
Proponents of surgery for asymptomatic patients worry that substernal goiter will grow and compress intrathoracic structures eventually if left untreated, although there are no studies documenting this process. This will require a longitudinal study, which we do not have for substernal goiter. Another worry is the presence of undiagnosed thyroid cancer within a substernal goiter. As patients age, if surgery performed later rather than earlier, surgery would be more difficult and would have a higher complication rate, and patients may evolve from lower surgical risk category to a higher by time.
When tracheal narrowing progresses to 35% or more, surgical intervention has been associated with 95% to 98% resolution of compressive symptoms. Tracheal compression of 35% or more has been advocated as an indication for surgical intervention. 35% reduction was not determined prospectively, but by comparing the narrowest tracheal size with the widest tracheal size on cross-sectional CT imaging.
Suppressive therapy (to lower TSH levels) with levothyroxine is ineffective. Radioactive iodine therapy has no role, even if the patient has hyperthyroidism. Radioactive iodine treatment can obscure or miss a malignancy. Radiation-induced thyroiditis in the closed chest cavity can theoretically cause respiratory compromise.
The definitive therapy is surgery, preferably total thyroidectomy. The cervical approach is used in the vast majority. A recent study reported that 78.3% of patients had a total thyroidectomy, 18.3% subtotal thyroidectomy, and 3.3% lobectomy. Definitive Surgical Management of Thyroid Disease in Adults Guidelines recommend total thyroidectomy for bilateral goiter as a principle, but there are some clinical scenarios that total thyroidectomy may not be feasible or possible. Patients require extra-cervical approach in 1% to 7.6% of the surgeries. The extra-cervical approach may range from partial sternotomy to thoracotomy. As substernal goiter surgery is challenging, it should be performed in a referral center. In a recent study, 17% of patients with substernal surgery required an extra-cervical approach showing that the rate is highly variable among institutions.
Mercante and coworkers proposed a classification system for substernal goiter. Grade I, if the lower border of the thyroid is above the aortic arch, Grade II if the lower border of the thyroid is between the convex and concave parts of the aortic arch and grade III if the lower border of the thyroid is below the concave part of the aortic arch. The need for an extra-cervical approach was significantly higher for grade II and III goiters. Indications for sternotomy are extension of goiter to the level or below the aortic arch, a dumbbell-shaped goiter, an iceberg shaped goiter with more than 70% of thyroid volume in the mediastinum, location in the posterior mediastinum, recurrent goiter, ectopic source of substernal goiter with blood supply from the mediastinal vessels rather than inferior thyroid artery, thyroid cancer with the possibility of invading mediastinal structures.
Surgery for substernal goiter is associated with more complications than surgery for cervical goiter. A recent study reported complications of substernal goiter surgery: postoperative bleeding (0.5%), permanent unilateral recurrent laryngeal nerve palsy (1.3%), bilateral recurrent laryngeal nerve palsy (0.6%), transient hypoparathyroidism (14%) and permanent hypoparathyroidism (4.1%). The mortality rate of substernal goiter surgery has been reported as high as 2.3% .
Depending on the patient’s symptoms, signs, clinical, laboratory, and radiologic features and surgical risk, a clinical decision should be made for expectant observation versus surgical intervention in asymptomatic patients. Surgery is required for symptomatic patients who have compression of intrathoracic vital structures. Patients with a positive Pemberton sign require surgery.
After thyroidectomy, levothyroxine replacement at a dose of 1.6 mcg/kg body weight for all patients and lower and gradually increasing doses for elderly or cardiac patients should be started.
There are no studies on the natural history of substernal goiter. Symptomatic patients with substernal goiter are operated precluding the study of natural history. No prospective studies are available that compare expectant monitoring with surgery. The concept of substernal goiter to enlarge and eventually cause symptoms and severe respiratory distress if left untreated has not been shown in any prospective study.
Prevention of goiter will also prevent the development of substernal goiter. The natural history of goiter is continued growth, nodule formation, and gain of functional autonomy with the transformation from nontoxic goiter to toxic multinodular goiter. The longer the goiter is present, the larger the size will be, and the larger the size of the goiter, the lower the TSH level will be. It is thought that gravity and negative intrathoracic pressure facilitates the extension of the thyroid to upper mediastinum. The prevention of substernal goiter is only possible with the prevention of goiter. The valid approaches at the individual level to prevent goiter is to ensure adequate iodine intake, 150 mcg/day for adults and adolescents, 220 mcg/day for pregnant women, 290 mcg/day for lactating women, 90 to 120 mcg/day children 1 to 11-year-old, 110 to 130 mcg/day for infants and avoid dietary or iatrogenic goitrogens. Goiter, due to autoimmune thyroid disease and inborn errors of metabolism, requires medical attention and cannot be prevented before they appear.
Patients should be educated about adequate dietary iodine intake, avoidance of goitrogens, and compliance with annual health exams.
There is consensus for surgical intervention for symptomatic patients, but there is disagreement on the management of asymptomatic patients. Future studies should compare the outcomes of expectant observation with monitoring versus surgery in asymptomatic subjects with substernal goiter.
A retrospective study measured thyroid volume by CT and concluded that intrathoracic thyroid volume of 162 cm and more below the thoracic inlet was a determining factor for thoracotomy. In the future, intrathoracic thyroid volume might be considered on the decision between cervical and extra cervical approach.
Substernal goiter is expected to be diagnosed more frequently and earlier because of widespread use of chest imaging and cancer screening. The patient with a substernal goiter should be referred to an endocrinologist for evaluation and management. If there is an indication for surgery, a surgical consultation, especially to a surgeon experienced in thyroid surgery is advised. If there are indications for extracervical approach, thoracic surgery consultation is required. Surgery for substernal goiter should be performed at tertiary institutions with experience in thyroid surgery and its complications.
|||Patel KN,Yip L,Lubitz CC,Grubbs EG,Miller BS,Shen W,Angelos P,Chen H,Doherty GM,Fahey TJ 3rd,Kebebew E,Livolsi VA,Perrier ND,Sipos JA,Sosa JA,Steward D,Tufano RP,McHenry CR,Carty SE, The American Association of Endocrine Surgeons Guidelines for the Definitive Surgical Management of Thyroid Disease in Adults. Annals of surgery. 2020 Mar; [PubMed PMID: 32079830]|
|||Chávez Tostado KV,Velázquez-Fernandez D,Chapa M,Pantoja Millán JP,Salazar MS,Herrera MF, Substernal Goiter: Correlation between Grade and Surgical Approach. The American surgeon. 2018 Feb 1; [PubMed PMID: 29580356]|
|||Sormaz İC,Uymaz DS,İşcan AY,Özgür İ,Salmaslıoğlu A,Tunca F,Şenyürek YG,Terzioğlu T, The Value of Preoperative Volumetric Analysis by Computerised Tomography of Retrosternal Goiter to Predict the Need for an Extra-Cervical Approach. Balkan medical journal. 2018 Jan 20; [PubMed PMID: 28840845]|
|||Doulaptsi M,Karatzanis A,Prokopakis E,Velegrakis S,Loutsidi A,Trachalaki A,Velegrakis G, Substernal goiter: Treatment and challenges. Twenty-two years of experience in diagnosis and management of substernal goiters. Auris, nasus, larynx. 2019 Apr; [PubMed PMID: 30055961]|
|||Sahbaz NA,Tutal F,Aksakal N,Acar S,Aksu KI,Barbaros U,Erbil Y, Cancer Frequency in Retrosternal Goiter. The American surgeon. 2017 Dec 1; [PubMed PMID: 29336760]|
|||Resende PN,de Menezes MB,Silva GA,Vianna EO, Pemberton Sign: A Recommendation to Perform Arm Elevation Spirometry With Flow-Volume Loops. Chest. 2015 Dec; [PubMed PMID: 26621294]|
|||De Filippis EA,Sabet A,Sun MR,Garber JR, Pemberton's sign: explained nearly 70 years later. The Journal of clinical endocrinology and metabolism. 2014 Jun; [PubMed PMID: 24646105]|
|||Landerholm K,Järhult J, Should asymptomatic retrosternal goitre be left untreated? A prospective single-centre study. Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society. 2015 Jun; [PubMed PMID: 24759378]|
|||Stang MT,Armstrong MJ,Ogilvie JB,Yip L,McCoy KL,Faber CN,Carty SE, Positional dyspnea and tracheal compression as indications for goiter resection. Archives of surgery (Chicago, Ill. : 1960). 2012 Jul; [PubMed PMID: 22430090]|
|||Polistena A,Sanguinetti A,Lucchini R,Galasse S,Monacelli M,Avenia S,Triola R,Bugiantella W,Rondelli F,Cirocchi R,Avenia N, Surgical approach to mediastinal goiter: An update based on a retrospective cohort study. International journal of surgery (London, England). 2016 Apr; [PubMed PMID: 26708863]|
|||Mercante G,Gabrielli E,Pedroni C,Formisano D,Bertolini L,Nicoli F,Valcavi R,Barbieri V, CT cross-sectional imaging classification system for substernal goiter based on risk factors for an extracervical surgical approach. Head [PubMed PMID: 20737483]|
|||Coskun A,Yildirim M,Erkan N, Substernal goiter: when is a sternotomy required? International surgery. 2014 Jul-Aug; [PubMed PMID: 25058777]|